The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Trial
Open accessAbstract
Objective: To assess the efficacy and safety of a remote electrical neuromodulation (REN) device for the acute treatment of migraine. Background: There is a significant unmet need for novel effective well‐tolerated acute migraine treatments. REN is a novel acute migraine treatment that stimulates upper arm peripheral nerves to induce conditioned pain modulation – an endogenous analgesic mechanism in which conditioning stimulation inhibits pain in remote body regions. A recent pilot study showed that REN can significantly reduce headache. We have conducted a randomized, double‐blind, sham‐controlled study to further evaluate the efficacy and safety of REN for the acute treatment of migraine. Methods: This was a randomized, double‐blind, sham‐controlled, multicenter study conducted at 7 sites in the United States and 5 sites in Israel. Two hundred and fifty‐two adults meeting the International Classification of Headache Disorders criteria for migraine with 2‐8 migraine headaches per month were randomized in a 1:1 ratio to active or sham stimulation. A smartphone‐controlled wireless device was applied for 30‐45 minutes on the upper arm within 1 hour of attack onset; electrical stimulation was at a perceptible but non‐painful intensity level. Migraine pain levels were recorded at baseline, 2, and 48 hours post‐treatment. Most bothersome symptoms (MBS) were also recorded. The primary efficacy endpoint was the proportion of participants achieving pain relief at 2 hours post‐treatment (improvement from severe or moderate pain to mild or none, or from mild pain to none). Relief of MBS and pain‐free at 2 hours were key secondary endpoints. Results: Active stimulation was more effective than sham stimulation in achieving pain relief (66.7% [66/99] vs 38.8% [40/103]; therapeutic gain of 27.9% [CI 95% , 15.6‐40.2]; P < .0001), pain‐free (37.4% vs 18.4%, P = .003), and MBS relief (46.3% vs 22.2%, P = .0008) at 2 hours post‐treatment. The pain relief and pain‐free superiority of the active treatment was sustained 48 hours post‐treatment. The incidence of device‐related adverse events was low and similar between treatment groups (4.8% [6/126] vs 2.4% [3/126], P = .499). Conclusions: REN provides superior clinically meaningful relief of migraine pain and MBS compared to placebo, offering a safe and effective non‐pharmacological alternative for acute migraine treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
Medication-overuse headache: a worldwide problem
Diener, H.-C., & Limmroth, V. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00824-5 · Cited by 455
Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study
Tassorelli, C., Grazzi, L., de Tommaso, M., Pierangeli, G., Martelletti, P., Rainero, I., Dorlas, S., Geppetti, P., Ambrosini, A., Sarchielli, P., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005857 · Cited by 254 · cited 3×
“REN may be an alternative acute migraine treatment with comparable or superior efficacy to commercially available neuromodulation devices.(16,25) REN has the potential to increase patient adherence, improve migraine management, and improve the health and quality of life of people with migraine.”
BackgroundResult
Cited by
Ailani, J., Burch, R. C., Robbins, M. S., & the Board of Directors of the American Headache Society (2021) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14153 · Cited by 766
Metadata
- Authors
- Yarnitsky, D., Dodick, D. W., Grosberg, B. M., Burstein, R., Ironi, A., Harris, D., Lin, T., & Silberstein, S. D.
- Venue
- Headache: The Journal of Head and Face Pain
- Publisher
- Wiley
- Published
- 2019-05-09
- Volume
- 59
- Issue
- 8
- Pages
- 1240-1252
- ISSN
- 0017-8748 (ISSN-L)
- 1526-4610
- OpenAlex
- W2944742536
- Cited by
- 160
- References
- 4
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Trial. https://app.cochat.ai/papers/10.1111/head.13551
- The paper
- Yarnitsky, D., Dodick, D. W., Grosberg, B. M., Burstein, R., Ironi, A., Harris, D., Lin, T., & Silberstein, S. D. (2019). Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Trial. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.13551
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.